

## 20. Screening for Thyroid Disease

### RECOMMENDATION

Routine screening for thyroid disease with thyroid function tests is not recommended for asymptomatic children or adults. There is insufficient evidence to recommend for or against screening for thyroid disease with thyroid function tests in high-risk patients, but recommendations may be made on other grounds (see *Clinical Intervention*). Clinicians should remain alert to subtle symptoms and signs of thyroid dysfunction when examining such patients. Screening for congenital hypothyroidism is discussed in Chapter 45.

### Burden of Suffering

Hyperthyroidism and hypothyroidism together account for considerable morbidity in the U.S. The total prevalence of these two disorders in adolescents and adults is estimated to be 1–4%; prevalence is higher in women and persons with Down syndrome, and increases with increasing age.<sup>1–10</sup> The annual incidence in adults has been estimated to be 0.05–0.1% for hyperthyroidism and 0.08–0.2% for hypothyroidism, with the higher incidences cited occurring in elderly women.<sup>2,11</sup> In adolescents, an incidence of 0.06%/year for these two disorders has been reported.<sup>5</sup> Symptoms of thyroid dysfunction, involving the nervous, cardiovascular, and gastrointestinal systems, may have an important impact on health and behavior.<sup>12</sup> Rarely, fatalities may occur due to thyroid storm in hyperthyroidism and myxedema coma in hypothyroidism.<sup>13</sup> Thyroid dysfunction during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes.<sup>14–18</sup> Most patients with thyroid dysfunction will present with typical clinical symptoms and signs within a few months of disease onset, although overt disease may occasionally be overlooked. Studies in which asymptomatic adults of all ages were screened in the clinical setting, often using older, less sensitive tests, detected previously unsuspected thyroid disease in 0.6–0.9% of persons screened.<sup>2,3,19,20</sup>

The clinical diagnosis of thyroid dysfunction can be more difficult in certain high-prevalence populations, including the elderly, those with Down syndrome, and postpartum women, possibly delaying treatment and risking complications.<sup>13</sup> Older persons may experience apathetic hyperthyroidism, without the goiter, ophthalmopathy, and signs of sympathetic nervous system hyperactivity typically seen in younger persons.<sup>21</sup> Typical

symptoms and signs of hypothyroidism, like fatigue, constipation, dry skin, and poor concentration, may be confused with symptoms of aging,<sup>22</sup> and may also occur less frequently in elderly hypothyroid patients.<sup>23</sup> Screening persons 60 years or older in the clinical setting detects previously unsuspected hyperthyroidism in 0.1–0.9% and hypothyroidism in 0.7–2.1%.<sup>2,19,24–27</sup> The clinical diagnosis of hypothyroidism may also be overlooked in patients with Down syndrome because some symptoms and signs, such as slow speech, thick tongue, and slow mentation, are typical findings of both conditions.<sup>6,7</sup> Screening persons with Down syndrome has detected previously unrecognized thyroid disease, primarily hypothyroidism, in 2.9% (range 0–6.5%).<sup>6,7,28</sup> Screening reveals thyroid dysfunction, primarily thyroiditis, in 4–6% of postpartum women.<sup>29–32</sup> This dysfunction is sometimes accompanied by nonspecific symptoms, such as fatigue, palpitations, impaired concentration, or depression,<sup>31,33,34</sup> that may be mistakenly attributed to the postpartum condition. Women with a personal or family history of thyroid or autoimmune disease, or with thyroid antibodies, are at increased risk for postpartum thyroid dysfunction.<sup>16,30,35–37</sup> Postpartum thyroid dysfunction is usually transient, but it may require short-term treatment to control symptoms.

Subclinical thyroid dysfunction as typically defined in the literature is a biochemical abnormality,<sup>38</sup> characterized by an abnormal level of thyroid-stimulating hormone (TSH) with otherwise normal thyroid tests and no clinical symptoms. Subclinical hypothyroidism, recognized by an elevated TSH level, is seen in 6–8% of adult women and 3% of adult men.<sup>1</sup> As with overt disease, the prevalence is higher in the elderly and in persons with Down syndrome.<sup>6,7,24,25,27,28,39–41</sup> Progression to overt hypothyroidism occurred in 2% of patients who had subclinical hypothyroidism without evidence of thyroid autoimmunity or prior thyroid-related disorders and who were followed for 2–15 years; in those with thyroid antibodies, however, progression occurs in about 5–7%/year, and in as many as 20–24%/year in elderly patients with antibodies.<sup>25,28,39,42–45</sup> Other than the risk of developing overt hypothyroidism, the importance of subclinical hypothyroidism is unknown. Case series have suggested adverse effects of an isolated elevated TSH level on blood lipid profile, myocardial function, and neuropsychiatric function,<sup>22,46–48</sup> but controlled observational studies have reported conflicting evidence regarding an association between subclinical hypothyroidism and any of these adverse effects.<sup>49–54</sup>

Subclinical hyperthyroidism, recognized by a subnormal TSH level, is seen in 0.2–5% of the elderly population; 1%/year progress to overt disease.<sup>11,40,55,56</sup> Subnormal levels of TSH are often transient, returning to normal without intervention.<sup>3,25,57</sup> There is limited evidence of risk from subclinical hyperthyroidism except when it is due to excessive thyroxine replacement. Case series have reported subclinical hyperthyroidism in a

number of patients with atrial fibrillation.<sup>58–61</sup> Older controlled observational studies found no association between subclinical hyperthyroidism and atrial fibrillation,<sup>62,63</sup> but a significant association was reported in one carefully controlled cohort study that used a sensitive TSH assay.<sup>57</sup> One controlled study reported a significantly lower total cholesterol level in patients with a subnormal TSH level,<sup>51</sup> suggesting a possible benefit of this condition.

### Accuracy of Screening Tests

Thyroid function tests to detect thyroid disease, including total thyroxine ( $TT_4$ ), free thyroxine ( $FT_4$ ), and TSH, are influenced by a variety of diagnostic and biologic factors that may affect their accuracy. For example, while  $TT_4$  is usually elevated in hyperthyroidism, it misses 5% of cases that are due to triiodothyronine ( $T_3$ ) toxicosis.<sup>64</sup>  $TT_4$  concentration is strongly influenced by the concentrations and binding affinities of thyroxine-binding globulin and other thyroid-binding proteins.<sup>38</sup> Falsely abnormal  $TT_4$  results often occur with conditions that affect these proteins, such as pregnancy, use of certain drugs, and nonthyroidal illness.<sup>38,64</sup>  $FT_4$  has the advantage over  $TT_4$  of being independent of thyroid-binding protein concentrations. Equilibrium dialysis (ED), regarded as the reference method for  $FT_4$ , is not suitable for routine screening due to its high cost.<sup>38,65</sup> Immunoassay or index (FTI) methods to estimate  $FT_4$  are simpler, less expensive than ED, and have specificities of 93–99% compared to ED;<sup>20,66–68</sup> these methods are not always independent of thyroid-binding protein concentrations, however,<sup>38,69</sup> and they may show substantial interlaboratory variation.<sup>65</sup>  $TT_4$  and  $FT_4$  cannot be reliably measured in ill patients, because a substantial proportion will have abnormal thyroid function in the absence of true thyroid disease, due to “sick euthyroid syndrome.”<sup>69–71</sup> Screening with  $TT_4$  or  $FT_4$  will generate many false-positive results in healthy populations.<sup>2,19,20,71</sup> With test specificities in the mid-90% range or lower, the low prevalence of previously unsuspected thyroid disease means that the likelihood of disease given an abnormal test will be quite low. In one study, thyroid disease requiring treatment was found in only 13% of those with abnormal FTI results.<sup>20</sup> Because  $TT_4$  and  $FT_4$  are normal by definition in subclinical thyroid dysfunction, they are not useful as screening tests for this condition.

The immunometric (“sensitive”) TSH (sTSH) assays detect low as well as high serum TSH levels, and have become the standard for detecting hyperthyroidism and hypothyroidism. They therefore offer promise as first-line thyroid screening tests. In unselected populations, sTSH has a sensitivity of 89–95% and specificity of 90–96% for overt thyroid dysfunction, as compared to reference standards incorporating clinical history, ex-

amination, repeat measurement, and/or additional testing including thyrotropin-releasing hormone tests.<sup>3,40,68</sup> In an asymptomatic older population, the likelihood of thyroid disease given an abnormal sTSH was only 7%, however, reflecting the low prevalence of disease in healthy people.<sup>40</sup> Acutely ill patients, pregnant women, and persons using certain drugs such as glucocorticoids may have false-positive sTSH results,<sup>38,72,73</sup> although specificity is better than for TT<sub>4</sub> and FT<sub>4</sub> when the three tests have been directly compared.<sup>38,74</sup> Newer sTSH assays reduce but do not eliminate false-positive diagnoses in such patients.<sup>75-77</sup> sTSH may respond slowly to abrupt changes in thyroid function,<sup>38</sup> such as those that occur after treatment for hyperthyroidism, but such changes are not generally relevant to the screening of asymptomatic patients.

### Effectiveness of Early Detection

Screening for occult thyroid dysfunction in adults would be valuable if there were clinical benefits of early treatment, including relief of previously unrecognized symptoms. We found no studies evaluating the treatment of hyperthyroidism detected by screening in asymptomatic persons, or of subclinical hyperthyroidism in persons with atrial fibrillation. Uncertainties about the benefits of treating hyperthyroidism detected by screening are particularly important because of the costs and potential adverse effects (e.g., agranulocytosis, induced hypothyroidism, surgical complications) of treatment with antithyroid medications, radioactive iodine ablation, or subtotal thyroidectomy.<sup>78,79</sup>

Several studies have evaluated the effectiveness of treating patients with subclinical hypothyroidism. Most of the subjects had previously identified thyroid disease, however, and the results may not apply to asymptomatic patients identified only by screening. In a randomized placebo-controlled trial of 33 women with subclinical hypothyroidism, all with a past history of treated hyperthyroidism, there were significant improvements in myocardial contractility and in previously unrecognized symptoms, but no significant changes in basal metabolic rate, pulse, body weight, skin texture, or serum lipid levels.<sup>80</sup> The long-term clinical importance of subtle changes in myocardial contractility is unknown. An uncontrolled experiment in 17 women identified by screening found a significantly improved mean clinical symptom score after treatment, mixed effects on myocardial function, and no effect on cholesterol, resting heart rate, body mass, or blood pressure.<sup>81</sup> Methodologic flaws make it difficult to interpret the results of this study. Uncontrolled experiments in adult patients, mostly women, with subclinical hypothyroidism due to previously identified thyroid disease have reported variable improvement in myocardial function but little effect on lipoproteins with thyroxine treatment.<sup>82-89</sup> A randomized con-

trolled trial measuring the effects of thyroid replacement on quality of life, lipids, neuropsychological function, bone mineral density, and myocardial function in elderly patients with subclinical hypothyroidism is ongoing (personal communication, Dr. R. Jaeshke, St. Joseph's Hospital, Hamilton, Ontario, August 4, 1995).

In children and adults with Down syndrome and subclinical hypothyroidism, a double-blind crossover placebo-controlled trial failed to document any cognitive, social, or physical changes attributable to 8–14 weeks of thyroxine treatment,<sup>41</sup> although treatment duration may have been inadequate to effect change. There is otherwise little evidence regarding the benefits of early intervention in these individuals.

Thyroxine replacement therapy can have adverse effects with even moderate degrees of overtreatment (as detected by low TSH or high TT<sub>4</sub> levels), including decreased bone density compared to matched controls.<sup>90–93</sup> Reduced bone density could increase the risk of fractures in the elderly, but one large series found no significant difference in risk for fractures (or for ischemic heart disease) in treated patients with normal TSH levels compared to those with suppressed TSH due to overtreatment.<sup>94</sup> The fracture rate in the two groups was the same as in the general population, while the risk of ischemic heart disease was higher in treated patients irrespective of TSH levels. The study was not designed to determine whether the latter finding was due to treatment or to the underlying disease, however. A small randomized controlled trial in postmenopausal women with subclinical hypothyroidism found no bone density reduction after 14 months of appropriate thyroxine treatment.<sup>95</sup> Evidence therefore suggests against an adverse impact of appropriate thyroxine treatment.

### Recommendations of Other Groups

No organizations recommend routine screening for thyroid disease in the general population, except screening newborns for congenital hypothyroidism (see Chapter 45). The American Academy of Family Physicians (AAFP)<sup>96</sup> and the American Association of Clinical Endocrinologists<sup>97</sup> recommend measuring thyroid function periodically in all older women. The policy of the AAFP is currently under review. The Canadian Task Force on the Periodic Health Examination recommends maintaining a high index of clinical suspicion for nonspecific symptoms consistent with hypothyroidism when examining perimenopausal and postmenopausal women.<sup>98</sup> The American College of Physicians recommends screening women over age 50 with one or more general symptoms that could be caused by thyroid disease.<sup>99</sup> The American College of Obstetricians and Gynecologists recommends that physicians and patients be aware of the symptoms and risk factors for postpartum thyroid dysfunction, and evaluate patients when in-

dicated.<sup>100</sup> The American Academy of Pediatrics recommends that children with Down syndrome have thyroid screening tests at 4–6 and 12 months of age, and annually thereafter.<sup>101</sup> The American Thyroid Association recommends screening thyroid function in elderly patients, postpartum women, and all patients with autoimmune disease or with a strong family history of thyroid disease, using serum TSH measurement.<sup>64,102</sup>

### Discussion

The prevalence of unsuspected thyroid disease in healthy people in the general population is very low. Despite the high specificity of thyroid function tests such as the newer TSH assays, their routine use in the asymptomatic general population results in many false-positive results. Because of the low prevalence of unsuspected disease, only 1 in 5–10 persons with abnormal screening tests will prove to have thyroid disease. Given the low risk, the lack of evidence that treatment of subclinical thyroid disease identified by screening results in important health benefits, and the potential adverse effects of treatment, screening the asymptomatic general population is not recommended.

The prevalence of thyroid disease is higher in certain populations, including elderly persons (particularly women), persons with Down syndrome, and postpartum women, and these patients might be candidates for thyroid function testing if the results could provide an explanation for nonspecific and insidious symptoms, such as fatigue, memory impairment, or depression, that might be attributed mistakenly to other medical or psychiatric causes. Clinicians should therefore maintain a high index of suspicion for such nonspecific symptoms, and for thyroid disease when these types of symptoms are found, when examining high-risk patients. There is, however, little evidence that routinely screening high-risk patients results in important clinical benefits.

### CLINICAL INTERVENTION

Routine screening for thyroid disease with thyroid function tests is not recommended for asymptomatic children or adults (“D” recommendation). This recommendation does not mean that clinicians should not monitor thyroid function in patients with a previous history of thyroid disease. There is insufficient evidence to recommend for or against screening for thyroid disease with thyroid function tests in high-risk patients, including elderly persons, postpartum women, and persons with Down syndrome, but recommendations may be made on other grounds, such as the higher prevalence of disease and the increased likelihood that symptoms of thyroid disease will be overlooked in these patients (“C” recommendation).

Clinicians should remain alert for subtle or nonspecific symptoms of thyroid dysfunction when examining such patients, and maintain a low threshold for diagnostic evaluation of thyroid function. Examples of such symptoms include easy fatigability, weight gain, dry skin or hair, cold intolerance, difficulty concentrating, depression, nervousness, and palpitations. If screening is performed, the preferred test is measurement of thyroid-stimulating hormone (TSH) using a sensitive immunometric or similar assay, because of its superior sensitivity and specificity. Screening for congenital hypothyroidism is discussed in Chapter 45.

The draft update of this chapter was prepared for the U.S. Preventive Services Task Force by Carolyn DiGuseppi, MD, MPH.

## REFERENCES

1. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. *Clin Endocrinol (Oxf)* 1977;7:481–493.
2. dos Remedios LV, Weber PM, Feldman R, et al. Detecting unsuspected thyroid dysfunction by the free thyroxine index. *Arch Intern Med* 1980;140:1045–1049.
3. Eggertsen R, Petersen K, Lundberg P-A, et al. Screening for thyroid disease in a primary care unit with a thyroid stimulating hormone assay with a low detection limit. *BMJ* 1988;297:1586–1592.
4. Baldwin DB, Rowett D. Incidence of thyroid disorders in Connecticut. *JAMA* 1978;239:742–744.
5. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. *Am J Med* 1991;91:363–370.
6. Dinani S, Carpenter S. Down's syndrome and thyroid disorder. *J Mental Deficiency Res* 1990;34:187–193.
7. Pozzan GB, Rigon F, Girelli ME, et al. Thyroid function in patients with Down syndrome: preliminary results from non-institutionalized patients in the Veneto region. *Am J Med Genet Suppl* 1990;7:57–58.
8. Falkenberg M, Kagedal B, Norr A. Screening of an elderly female population for hypo- and hyperthyroidism by use of a thyroid hormone panel. *Acta Med Scand* 1983;214:361–365.
9. Sawin CT, Castelli WP, Hershman JM, et al. The aging thyroid: thyroid deficiency in the Framingham Study. *Arch Intern Med* 1985;145:1386–1388.
10. Petersen K, Lindstedt G, Lundberg P-A, et al. Thyroid disease in middle-aged and elderly Swedish women: thyroid-related hormones, thyroid dysfunction and goitre in relation to age and smoking. *J Intern Med* 1991;229:407–414.
11. Sundbeck G, Lundberg P-A, Lindstedt G, et al. Incidence and prevalence of thyroid disease in elderly women: results from the longitudinal population study of elderly people in Gothenburg, Sweden. *Age Ageing* 1991; 20: 291–298.
12. Gavin LA. The diagnostic dilemmas of hyperthyroxinemia and hypothyroxinemia. *Adv Intern Med* 1988;33:185–204.
13. Gavin LA. Thyroid crises. *Med Clin North Am* 1991;75:179–193.
14. Leung AS, Millar LK, Koonings PP, et al. Perinatal outcome in hypothyroid pregnancies. *Obstet Gynecol* 1993; 81:349–353.
15. Glinoe D, Fernandez Soto M, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. *J Clin Endocrinol Metab* 1991;73:421–427.
16. Glinoe D, Riahi M, Grun J-P, et al. Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. *J Clin Endocrinol Metab* 1994;79:197–204.
17. Davis LE, Lucas MJ, Hankins GDV, et al. Thyrotoxicosis complicating pregnancy. *Am J Obstet Gynecol* 1989; 160:63–70.
18. Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. *Obstet Gynecol* 1988;72:108–112.
19. Nolan JP, Tarsa NJ, DiBenedetto G. Case-finding for unsuspected thyroid disease: costs and health benefits. *Am J Clin Pathol* 1985;83:346–355.

20. Fukazawa H, Sakurada T, Yoshida K, et al. Free thyroxine estimation for the screening of hyper- and hypothyroidism in an adult population. *Tohoku J Exp Med* 1986;148:411-420.
21. Sawin CT. Thyroid dysfunction in older persons. *Adv Intern Med* 1991;37:223-248.
22. Levy EG. Thyroid disease in the elderly. *Med Clin North Am* 1991;75:151-167.
23. Doucet J, Trivalle C, Chassagne P, et al. Does age play a role in clinical presentation of hypothyroidism. *J Am Geriatr Soc* 1994;42:984-986.
24. Bembien DA, Winn P, Hamm RM, et al. Thyroid disease in the elderly. Part 1. Prevalence of undiagnosed hypothyroidism. *J Fam Pract* 1994;38:577-582.
25. Parle JV, Franklyn JA, Cross KW, et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. *Clin Endocrinol (Oxf)* 1991;34:77-83.
26. Bahemuka M, Hodkinson HM. Screening for hypothyroidism in elderly inpatients. *BMJ* 1975;2:601-603.
27. Drinka PJ, Nolten WE. Prevalence of previously undiagnosed hypothyroidism in residents of a mid-western nursing home. *South Med J* 1990;83:1259-1261.
28. Selikowitz M. A five-year longitudinal study of thyroid function in children with Down syndrome. *Dev Med Child Neurol* 1993;35:396-401.
29. Gerstein HC. How common is postpartum thyroiditis? *Arch Intern Med* 1990;150:1397-1400.
30. Walfish PG, Meyerson J, Provias JP, et al. Prevalence and characteristics of post-partum thyroid dysfunction: results of a survey from Toronto, Canada. *J Endocrinol Invest* 1992;15:265-272.
31. Amino N, Mori H, Iwatani Y, et al. High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. *N Engl J Med* 1982;306:849-852.
32. Jansson R, Bernander S, Karlsson A, et al. Autoimmune thyroid dysfunction in the postpartum period. *J Clin Endocrinol Metab* 1984;58:681-687.
33. Hayslip CC, Fein HG, O'Donnell VM, et al. The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction. *Am J Obstet Gynecol* 1988;159:203-209.
34. Roti E, Emerson CH. Clinical review 29: postpartum thyroiditis. *J Clin Endocrinol Metab* 1992;74:3-5.
35. Hidaka Y, Tamaki H, Iwatani Y, et al. Prediction of post-partum Graves' thyrotoxicosis by measurement of thyroid stimulating antibody in early pregnancy. *Clin Endocrinol (Oxf)* 1994;41:15-20.
36. Solomon BL, Fein HG, Smalldridge RC. Usefulness of antimicrosomal antibody titers in the diagnosis and treatment of postpartum thyroiditis. *J Fam Pract* 1993;36:177-182.
37. Fung HYM, Kologlu M, Collison K, et al. Postpartum thyroid dysfunction in Mid Glamorgan. *BMJ* 1988;296:241-244.
38. Bayer MF. Effective laboratory evaluation of thyroid status. *Med Clin North Am* 1991;75:1-26.
39. Rosenthal MJ, Hunt WC, Garry PJ, et al. Thyroid failure in the elderly. *JAMA* 1987;258:209-213.
40. Okamura K, Ueda K, Sone H, et al. A sensitive thyroid stimulating hormone assay for screening of thyroid functional disorder in elderly Japanese. *J Am Geriatr Soc* 1989;37:317-322.
41. Tirosh E, Taub Y, Scher A, et al. Short-term efficacy of thyroid hormone supplementation for patients with Down syndrome and low-borderline thyroid function. *Am J Ment Retard* 1989;93:652-656.
42. Tunbridge WMG, Brewis M, French JM, et al. Natural history of autoimmune thyroiditis. *BMJ (Clin Res)* 1981;282: 258-262.
43. Helfand M, Crapo LM. Screening for thyroid disease. *Ann Intern Med* 1990;112:840-849.
44. Gordin A, Lamberg BA. Spontaneous hypothyroidism in symptomless autoimmune thyroiditis. A long-term follow-up study. *Clin Endocrinol (Oxf)* 1981;15:537-543.
45. Drinka PJ, Nolten WE, Voeks SK, et al. Follow-up of mild hypothyroidism in a nursing home. *J Am Geriatr Soc* 1991;39:264-266.
46. Pallas D, Koutras DA, Adamopoulos P, et al. Increased mean serum thyrotropin in apparently euthyroid hypercholesterolemic patients: does it mean occult hypothyroidism? *J Endocrinol Invest* 1991;14:743-746.
47. Haggerty JJ Jr, Garbutt JC, Evans DL, et al. Subclinical hypothyroidism: a review of neuropsychiatric aspects. *Int J Psychiatr Med* 1990;20:193-208.
48. Glueck CJ, Lang J, Tracy T, et al. The common finding of covert hypothyroidism at initial clinical evaluation for hyperlipoproteinemia. *Clin Chim Acta* 1991;201:113-122.
49. Althaus BU, Staub JJ, Ryff-De Leche A, et al. LDL/HDL changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. *Clin Endocrinol (Oxf)* 1988;28:157-163.
50. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. *Am J Med* 1992;92:631-642.



51. Parle JV, Franklyn JA, Cross KW, et al. Circulating lipids and minor abnormalities of thyroid function. *Clin Endocrinol (Oxf)* 1992;37:411–414.
52. Tunbridge WMG, Evered DC, Hall R, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. *Clin Endocrinol (Oxf)* 1977;7:495–508.
53. Osterweil D, Syndulko K, Cohen SN, et al. Cognitive function in non-demented older adults with hypothyroidism. *J Am Geriatr Soc* 1992;40:325–335.
54. Kutty KM, Bryant DG, Farid NR. Serum lipids in hypothyroidism—a reevaluation. *J Clin Endocrinol Metab* 1978;46: 55–56.
55. Sawin CT, Geller A, Kaplan MM, et al. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. *Arch Intern Med* 1991;151:165–168.
56. Sundbeck G, Jagenburg R, Johansson P-M, et al. Clinical significance of low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men. *Arch Intern Med* 1991;151: 549–556.
57. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* 1994;331:1249–1252.
58. Forfar JC, Feek CM, Miller HC, et al. Atrial fibrillation and isolated suppression of the pituitary-thyroid axis: response to specific antithyroid therapy. *Int J Cardiol* 1981;1:43–48.
59. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of “idiopathic” atrial fibrillation. *Am J Cardiol* 1979;44:9–12.
60. Ciaccheri M, Cecchi F, Arcangeli C, et al. Occult thyrotoxicosis in patients with chronic and paroxysmal isolated atrial fibrillation. *Clin Cardiol* 1984;7:413–416.
61. Bruce SA, Rangedara DC, Lewis RR, et al. Hyperthyroidism in elderly patients with atrial fibrillation and normal thyroid hormone measurements. *J Roy Soc Med* 1987;80:74–76.
62. Tajiri J, Hamasaki S, Shimada T, et al. Masked thyroid dysfunction among elderly patients with atrial fibrillation. *Jpn Heart J* 1986;27:183–190.
63. Davies AB, Williams I, John R, et al. Diagnostic value of thyrotrophin releasing hormone tests in elderly patients with atrial fibrillation. *BMJ* 1985;291:773–776.
64. Surks MI, Chopra IJ, Mariash CN, et al. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. *JAMA* 1990;263:1529–1532.
65. Hay ID, Bayer MF, Kaplan MM, et al. American Thyroid Association assessment of current free thyroid hormone and thyrotropin measurements and guidelines for future clinical assays. *Clin Chem* 1991;37: 2002–2008.
66. Ericsson U-B, Thorell JI. A prospective critical evaluation of in vitro thyroid function tests. *Acta Med Scand* 1986; 220:47–56.
67. Wilke TJ, Eastment HT. Discriminative ability of tests for free and total thyroid hormones in diagnosing thyroid disease. *Clin Chem* 1986;32:1746–1750.
68. de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. *Arch Intern Med* 1989;149:526–532.
69. Cavalieri RR. The effects of nonthyroid disease and drugs on thyroid function tests. *Med Clin North Am* 1991;75: 27–39.
70. Small M, Buchanan L, Evans R. Value of screening thyroid function in acute medical admissions to hospital. *Clin Endocrinol (Oxf)* 1990;32:185–191.
71. Drinka PJ, Nolten WE, Voeks S, et al. Misleading elevation of the free thyroxine index in nursing home residents. *Arch Pathol Lab Med* 1991;115:1208–1211.
72. Finucane P, Rudra T, Church H, et al. Thyroid function tests in elderly patients with and without an acute illness. *Age Ageing* 1989;18:398–402.
73. Ehrmann DA, Weinberg M, Sarne DH. Limitations to the use of a sensitive assay for serum thyrotropin in the assessment of thyroid status. *Arch Intern Med* 1989;149:369–372.
74. Klee GG, Hay ID. Sensitive thyrotropin assays: analytic and clinical performance criteria. *Mayo Clin Proc* 1988;63: 1123–1132.
75. Franklyn JA, Black EG, Betteridge J, et al. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. *J Clin Endocrinol Metab* 1994;78:1368–1371.
76. Spencer CA, LoPresti JS, Guttler RB, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *J Clin Endocrinol Metab* 1990;70:453–460.

77. Wilkinson E, Rae PWH, Thomson KJT, et al. Chemiluminescent third-generation assay (Amerlite TSH-30) of thyroid-stimulation hormone in serum or plasma assessed. *Clin Chem* 1993;39:2166-2173.
78. Baker B, Shapiro B, Fig LM, et al. Unusual complications of antithyroid drug therapy: four case reports and review of literature. *Thyroidology* 1989;1:17-26.
79. Franklyn JA. The management of hyperthyroidism. *N Engl J Med* 1994;330:1731-1738.
80. Cooper DS, Halpern R, Wood LC, et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. *Ann Intern Med* 1984;101:18-24.
81. Nystrom E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with "subclinical" hypothyroidism. *Clin Endocrinol* 1988;29:63-76.
82. Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. *Clin Endocrinol (Oxf)* 1990;33:519-523.
83. Bell GM, Todd WT, Forfar JC, et al. End-organ responses to thyroxine therapy in subclinical hypothyroidism. *Clin Endocrinol* 1985;22:83-89.
84. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. *Arch Intern Med* 1990;150:2097-2100.
85. Forfar JC, Wathen CG, Todd WTA, et al. Left ventricular performance in subclinical hypothyroidism. *Q J Med* 1985;57:857-865.
86. Franklyn JA, Daykin J, Betteridge J, et al. Thyroxine replacement therapy and circulating lipid concentrations. *Clin Endocrinol (Oxf)* 1993;38:453-459.
87. Ridgway EC, Cooper DS, Walker H, et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. *J Clin Endocrinol Metab* 1981;53:1238-1242.
88. Nilsson G, Nordlander S, Levin K. Studies on subclinical hypothyroidism with special reference to the serum lipid pattern. *Acta Med Scand* 1976;200:63-67.
89. Lithell H, Bobberg J, Hellsing K, et al. Serum lipoprotein and apolipoprotein concentrations and tissue lipoprotein-lipase activity in overt and subclinical hypothyroidism: the effect of substitution therapy. *Eur J Clin Invest* 1981;11: 3-10.
90. Paul TL, Kerrigan J, Kelly AM, et al. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. *JAMA* 1988;259:3137-3141.
91. Stall GM, Harris S, Sokoll LJ, et al. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. *Ann Intern Med* 1990;113:265-269.
92. Ross DS. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. *Mayo Clin Proc* 1988;63:1223-1239.
93. Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women: effects of estrogen. *JAMA* 1994;271:1245-1249.
94. Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. *Clin Endocrinol (Oxf)* 1992;37:500-503.
95. Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. *Am J Med* 1993;95:385-388.
96. American Academy of Family Physicians. Age charts for periodic health examination. Kansas City, MO: American Academy of Family Physicians, 1994. (Reprint no. 510.)
97. American Association of Clinical Endocrinologists. Clinical practice guidelines for the evaluation of hyperthyroidism and hypothyroidism. Jacksonville, FL: American Association of Clinical Endocrinologists and American College of Endocrinology, 1995.
98. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group, 1994:611-618.
99. Eddy DM. Common screening tests. Philadelphia: American College of Physicians, 1991:406-408.
100. American College of Obstetricians and Gynecologists. Thyroid disease in pregnancy. Technical Bulletin no. 181. Washington, DC: American College of Obstetricians and Gynecologists, 1993.
101. American Academy of Pediatrics Committee on Genetics. Health supervision for children with Down syndrome. *Pediatrics* 1994;93:855-859.
102. Becker DV, Bigos ST, Gaitan E, et al. Optimal use of blood tests for assessment of thyroid function [letter]. *JAMA* 1993;269:2736.